Membranous Nephropathy Market Insights 2032 by Delveinsight | Argenx, Zai Lab Pty Ltd

The market size of Membranous Nephropathy is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as BeiGene, Reistone Biopharma Company Limited, Hoffmann-La Roche, Gilead Sciences, Mallinckrodt, Mayo Clinic, Genentech Inc., GlaxoSmithKline, Roche Pharma AG, Apellis Pharmaceuticals Inc., and others…

[Nevada, United States] – DelveInsight’s “Membranous Nephropathy Market Insights, Epidemiology, and Market Forecast 2032.” report offers a detailed examination of Membranous Nephropathy, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Membranous Nephropathy Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Membranous Nephropathy Market Forecast

Key Findings from the Membranous Nephropathy Market Report:

• The Membranous Nephropathy market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2019-2032).

• In September, 2024: Shanghai Jiaolian Drug Research and Development Co., Ltd announced that the purpose of their study is to evaluate the efficacy and safety of B007 in the Treatment of Primary Membranous Nephropathy

• In August, 2024: BeiGene announced that the primary objective of their study is to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and to evaluate the efficacy of zanubrutinib compared with tacrolimus as measured by complete remission rate, in participants with primary membranous nephropathy who are on optimal supportive care.

• In August, 2024: Hoffmann-La Roche announced that their study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants with primary membranous nephropathy (pMN).

• In August, 2024: Hansa Biopharma AB announced that a Phase 3 trial evaluating renal function in patients with severe anti-GBM disease comparing imlifidase and standard of care (SoC) with SoC alone. All patients will remain in the trial for 24 months.

• In June, 2024: Apellis Pharmaceuticals, Inc. announced that a Phase II trial assessing the safety and preliminary efficacy of daily APL-2 subcutaneous infusion administered for 16 weeks with a 6 month safety follow up, in patients with glomerulopathies

• In a study by Storrar et al. (2022), 178 patients with primary membranous nephropathy were identified over two decades. As per the results of this study, remission (partial or complete) was achieved in 134 (75.3%), either spontaneous in 60 (33.7%) or after treatment with immunosuppression in 74 (41.6%), and of these, 57 (42.5%) relapsed. Progression to renal replacement therapy was seen in 10.1%, with mortality in 29.8%.

• In 2023, the prevalent population of Idiopathic Membranous Nephropathy in the United States was found to be around 29,000, which will increase to 31,227 cases by 2034.

• Among EU4 and the UK, PLA2R and THSD7A antigens were detected in nearly 18,000 and 1,000 IMN patients, respectively.

• Key Membranous Nephropathy Companies are as follows: Argenx, Zai Lab Pty Ltd., Shanghai Jiaolian Drug Research and Development Co. Ltd., Shanghai Pharmaceuticals Holding Co., Ltd, Acelyrin, Beijing Mabworks Biotech Co., Ltd., Cerium Pharmaceuticals Inc., BeiGene, Reistone Biopharma Company Limited, Hoffmann-La Roche, Gilead Sciences, Mallinckrodt, Mayo Clinic, Genentech Inc., GlaxoSmithKline, Roche Pharma AG, Apellis Pharmaceuticals Inc., and others.

• Key Membranous Nephropathy Therapies are as follow: placebo, VB119, Rituximab, MIL62, Cyclosporine, B007, Cyclosporin Capsules, Rituximab, SNP-ACTH (1-39) Gel, Zanubrutinib, Tacrolimus, SHR1459, Placebo, Obinutuzumab, Tacrolimus, Methylprednisolone, Filgotinib, Lanraplenib, belimumab, povetacicept, WAL0921

• Launching multiple stage Membranous Nephropathy pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Membranous Nephropathy Market Overview:

The Membranous Nephropathy Drugs Market report provides current treatment practices, emerging drugs, Membranous Nephropathy market share of the individual therapies, current and forecasted Membranous Nephropathy market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Membranous Nephropathy treatment market practice/algorithm, Membranous Nephropathy market drivers and market barriers and Membranous Nephropathy unmet needs to curate best of the opportunities and assesses the underlying potential of the Membranous Nephropathy drugs market.

Membranous Nephropathy Drugs Uptake and Pipeline Development Activities:

The drugs uptake section highlights the adoption rate of newly launched or anticipated drugs during the study period. The report includes information on market uptake by drugs, patient uptake by therapies, and sales for each drug. Additionally, it offers insights into the Fabry Disease pipeline, examining therapeutic candidates at various stages and the key companies engaged in their development.

Membranous Nephropathy Therapies and Key Companies:

• Placebo: argenx

• VB119: Tenet Medicines

• Rituximab: Mayo Clinic

• MIL62, Cyclosporine: Beijing Mabworks Biotech Co., Ltd.

• B007, Cyclosporin Capsules: Shanghai Jiaolian Drug Research and Development Co., Ltd

• Rituximab, SNP-ACTH (1-39) Gel: Cerium Pharmaceuticals, Inc.

• Zanubrutinib, Tacrolimus: BeiGene

• SHR1459, Placebo: Reistone Biopharma Company Limited

• Obinutuzumab, Tacrolimus, Methylprednisolone: Hoffmann-La Roche

• Filgotinib, Lanraplenib: Gilead Sciences

• Belimumab: GlaxoSmithKline

• Povetacicept: Alpine Immune Sciences, Inc.

• WAL0921: Walden Biosciences

For more information about Membranous Nephropathy companies working in the treatment market, visit Membranous Nephropathy Clinical Trials

Membranous Nephropathy Epidemiology:

The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2019 to 2032. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Membranous Nephropathy.

Membranous Nephropathy Epidemiology Segmentation:

The Membranous Nephropathy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Membranous Nephropathy

• Prevalent Cases of Membranous Nephropathy by severity

• Gender-specific Prevalence of Membranous Nephropathy

• Diagnosed Cases of Episodic and Chronic Membranous Nephropathy

Membranous Nephropathy Market Drivers and Barriers:

The Membranous Nephropathy Market Forecast report highlights key drivers and barriers shaping the Membranous Nephropathy market dynamics, providing insights into factors influencing growth and challenges that may be encountered.

Scope of the Membranous Nephropathy Market Report:

• Study Period: 2019–2032

• Coverage: 7MM (The United States, EU5, and Japan)

• Key Membranous Nephropathy Companies: Argenx, Zai Lab Pty Ltd., Shanghai Jiaolian Drug Research and Development Co. Ltd., Shanghai Pharmaceuticals Holding Co., Ltd, Acelyrin, Beijing Mabworks Biotech Co., Ltd., Cerium Pharmaceuticals Inc., BeiGene, Reistone Biopharma Company Limited, Hoffmann-La Roche, Gilead Sciences, Mallinckrodt, Mayo Clinic, Genentech Inc., GlaxoSmithKline, Roche Pharma AG, Apellis Pharmaceuticals Inc., and others.

• Key Membranous Nephropathy Therapies: placebo, VB119, Rituximab, MIL62, Cyclosporine, B007, Cyclosporin Capsules, Rituximab, SNP-ACTH (1-39) Gel, Zanubrutinib, Tacrolimus, SHR1459, Placebo, Obinutuzumab, Tacrolimus, Methylprednisolone, Filgotinib, Lanraplenib, belimumab, povetacicept, WAL0921

• Membranous Nephropathy Therapeutic Assessment: Current marketed and emerging therapies

• Membranous Nephropathy Market Dynamics: Membranous Nephropathy Market drivers and Membranous Nephropathy barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Membranous Nephropathy Unmet Needs: Insights into unmet needs, KOL’s views, Analyst’s views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Membranous Nephropathy market outlook, drug uptake, treatment scenario, and epidemiology trends, Membranous Nephropathy Market Forecast

About DelveInsight:

DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:

Company Name: DelveInsight Business Research LLP

Contact Person: Ram Kapoor

Email: info@delveinsight.com

Contact No.: +91-9650213330

City: 304 S. Jones Blvd #2432, Las Vegas

State: Nevada (89107)

Country: United States

Website: https://www.delveinsight.com/consulting